The Tumor Immunity Therapy Market is being transformed by advances in immunology, molecular biology, and cancer research. Tumor immunity therapy encompasses several approaches designed to strengthen the immune system's ability to identify and destroy cancer cells. The growing limitations of traditional cancer treatments in certain patient populations are increasing interest in therapies that provide more targeted and biologically specific mechanisms of action.

The market is projected to experience substantial expansion during the coming years. WiseGuyReports reports a market value of USD 21.22 billion in 2024 and forecasts growth to USD 150.41 billion by 2032, representing a CAGR of 27.74%. The expansion is associated with rising cancer incidence, increasing immunotherapy adoption, technological progress, and greater healthcare expenditure.

Checkpoint inhibitors remain one of the most influential technologies within the market. By interfering with immune checkpoint pathways, these therapies can help restore immune activity against tumor cells. T-cell adoptive immunotherapy is another important area, with engineered or selected immune cells being used to target cancer more precisely. WiseGuyReports estimates that T-cell adoptive immunotherapy could reach USD 18.45 billion by 2032.

Oncolytic viruses and immune modulators are also gaining momentum. Oncolytic viruses are designed to selectively affect tumor cells while stimulating immune responses, whereas immune modulators can alter immune activity to improve the body's ability to fight cancer. These approaches provide additional opportunities for innovation and combination treatment development.

The route of administration represents another important market segment. Intravenous administration has historically accounted for the largest revenue contribution because it enables therapies to be delivered directly into the bloodstream. However, intratumoral administration is expected to record rapid growth because targeted delivery directly into tumors may provide therapeutic advantages in selected applications.

The competitive environment includes major pharmaceutical and biotechnology companies such as Roche, Merck, Bristol-Myers Squibb, Novartis, and Pfizer. These companies are investing in research, clinical development, strategic partnerships, and commercialization of innovative oncology products.

Government funding is another factor supporting market development. Increased public and private investment in cancer research can accelerate the discovery and clinical development of new immunotherapeutic technologies. Collaboration between academic institutions, biotechnology companies, and pharmaceutical organizations is also helping move promising research toward clinical applications.

As cancer treatment increasingly moves toward precision and personalized medicine, tumor immunity therapy is expected to play an expanding role. Advances in biomarkers, artificial intelligence-assisted drug discovery, cell therapy, and combination treatment strategies could create new opportunities and strengthen the long-term growth prospects of this market.